Bob Lechleider
Directeur Technique/Scientifique/R&D chez IMMUNOME, INC.
Profil
Bob Lechleider is currently the Chief Medical Officer at Immunome, Inc. He previously worked as the Senior Vice President-Clinical Development at Seagen Inc. and as the Chief Medical Officer at OncoResponse, Inc. from 2020 to 2023.
Dr. Lechleider completed his undergraduate degree at Princeton University and obtained a doctorate from the University of Illinois College of Medicine.
Postes actifs de Bob Lechleider
Sociétés | Poste | Début |
---|---|---|
IMMUNOME, INC. | Directeur Technique/Scientifique/R&D | 19/10/2023 |
Anciens postes connus de Bob Lechleider
Sociétés | Poste | Fin |
---|---|---|
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | Directeur Technique/Scientifique/R&D | 01/10/2023 |
SEAGEN INC. | Directeur Technique/Scientifique/R&D | 01/01/2023 |
Formation de Bob Lechleider
Princeton University | Undergraduate Degree |
University of Illinois College of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
IMMUNOME, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | Health Technology |
Seagen Inc.
Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |